

In re: Nicolette  
USSN: 10/041,977  
Filed: January 9, 2002  
Page 3

**IN THE CLAIMS**

All pending claims are set forth below. Please cancel claims 19 and 24 without prejudice. Please amend claims 1, 8, 9, 20, 25 and 26 as follows:

1. (currently amended) A method for identifying a cytotoxic T cell epitope comprising the steps in order of:

a) contacting a population of at least two cytotoxic T cells having the same MHC-haplotype restriction with a quantity of molecule released from a solid phase support, wherein said solid phase support is present in

i) a library of molecules, which molecules are attached to a plurality of solid phase supports by a releasable linker, wherein each of said solid phase supports is attached to comprising a plurality of identical copies of a single species of molecule, and wherein the structure of the molecule can be determined is determinable, which library of molecules contains a conserved structural motif corresponding to a structural motif characteristic of peptides that associate with the MHC-haplotype to which the cytotoxic T cells are restricted; wherein said quantity of released molecule consists of an amount less than the plurality of said single species of molecule attached to said solid support; and

ii) antigen presentation means, which antigen presentation means correspond to the MHC-haplotype to which the cytotoxic T cells are restricted;

wherein the solid phase supports of the library are in separate fractions;

b) cleaving at least a portion of the releasable linker so as to release at least a portion of the molecule;

c) evaluating whether the cytotoxic T cells recognize a molecule present in one or more of the fractions of the library of molecules;

d) isolating one or more solid phase support(s) from the fractions; and

e) determining the structure of a molecule on a solid phase support isolated from the fraction detecting cytotoxic T cell activation effected by the formation of a complex of a cytotoxic T cell, a single species of released molecule, and said antigen presentation means; and

c) determining the structure of said molecule.

BEST AVAILABLE COPY

*In re: Nicolette*  
USSN: 10/041,977  
Filed: January 9, 2002  
Page 4

2. (original) The method according to claim 1, wherein the cytotoxic T cells are selected from the group consisting of
  - a) polyclonal T cells isolated from a site of cytotoxic T cell infiltration from an individual;
  - b) cells isolated from a site of cytotoxic T cell infiltration from two or more individuals, which two or more individuals share an MHC haplotype;
  - c) two or more cytotoxic T cell lines; and
  - d) any combination thereof.
3. (withdrawn) The method according to claim 2, wherein the site of cytotoxic T cell infiltration is a tumor.
4. (original) The method according to claim 1, wherein the molecules are peptides.
5. (original) The method according to claim 4, wherein the peptides comprise subunits selected from the group consisting of glycine, L-amino acids, D-amino acids, non-classical amino acids, and peptidomimetics.
6. (original) The method according to claim 1, wherein the solid phase support is selected from the group consisting of polystyrene resin, poly( dimethylacryl)amide-grafted styrene-codivinylbenzene resin, polyamide resin, polystyrene resin grafted with polyethylene glycol, and polydimethylacrylamide resin.
7. (original) The method according to claim 1, wherein the releasable linker releases upon exposure to an acid, a base, a nucleophile, an electrophile, light, an oxidizing agent, a reducing agent, or an enzyme.
8. (currently amended) The method according to claim 1, wherein the structural motif contained in the library of molecules is selected from the group consisting of LXXXXXX' (SEQ ID NO: 1); RXXXXXX + (SEQ ID NO: 2); X(D, E)XXXXXX(F, K; Y) (SEQ ID NO: 3); RXXXXXXXL (SEQ ID NO: 4); X(K, R)XXXXXX(L, I) (SEQ ID NO: 5); (M, L)XXXXXXK (SEQ ID

*In re: Nicolete*

USSN: 10/041,977

Filed: January 9, 2002

Page 5

NO: 6); EXXXXXX(Y, F) (SEQ ID NO: 7); XPXXXXX(F, H, W, Y) (SEQ ID NO:8); and (L, I)XXXXX(H, K) (SEQ ID NO:9); wherein X indicates any amino acid residue, and + indicates a positively charged amino acid residue.

9. (currently amended) The method according to claim 4, wherein ~~a limited~~ the number of representative amino acid residues that are incorporated in the peptides of the library is limited.

10. (original) The method according to claim 9, wherein positively charged amino acid residues are substituted with an amino acid selected from the group consisting of lysine, arginine, and histidine; negatively charged amino acid residues are substituted with an amino acid selected from the group consisting of aspartic acid and glutamic acid; neutral, polar amino acid residues are substituted with an amino acid selected from the group consisting of asparagine, glutamine, serine, threonine, tyrosine, glycine and cysteine; nonpolar amino acid residues are substituted with an amino acid selected from the group consisting of alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine.

11. (original) The method according to claim 10, wherein the nonpolar, aromatic amino acid residues are substituted with an amino acid selected from the group consisting of tyrosine, threonine, and tryptophan; and the nonpolar aliphatic amino acid residues are substituted with an amino acid selected from the group consisting of alanine, valine, leucine, isoleucine, proline, and methionine.

12. (original) The method according to claim 1, further comprising a coding molecule attached to each to each solid phase support of the library, which coding molecule defines the structure of the molecule attached to the solid phase support by the releasable linker.

13. (original) The method according to claim 12, wherein the coding molecule is selected from the group consisting of a peptide and an oligonucleotide.

14. (original) The method according to claim 10, wherein the coding molecule is an inert molecular tag that can be decoded by gas-phase chromatography.

*In re: Nicolette*  
USSN: 10/041,977  
Filed: January 9, 2002

Page 6

15. (original) The method according to claim 1, wherein the antigen presentation means is selected from the group consisting of a purified MHC class I molecule complexed to  $\beta_2$ microglobulin; an intact antigen presenting cell; and a foster antigen presenting cell.

16. (original) The method according to claim 1, wherein the antigen presentation means is a foster antigen presenting cell.

17. (original) The method according to claim 16, wherein the foster antigen presenting cell lacks antigen processing activity, whereby it expresses MHC molecules free of bound peptides.

18. (original) The method according to claim 17, wherein the foster antigen presenting cell is cell line 174xCEM. T2.

19. (canceled)

20. (currently amended) The method according to claim 1, wherein cytotoxic T cell activation is detected by a method selected from the group consisting of  $^{3\text{H}}$ -thymidine incorporation; metabolic activity detected by conversion of MTT to formazan blue; increased cytokine mRNA expression; increased cytokine protein production; and chromium release by target cells.

21. (original) The method of claim 1, wherein the structure of the molecule is determined by analyzing a portion of the molecule remaining on the solid phase support

22. (original) The method according to claim 4, wherein a sequence of the peptide is determined by sequencing a portion of the peptide remaining on the solid phase support

23. (original) The method according to claim 12, wherein the structure of the molecule is determined by analyzing the structure of the coding molecule

24. (canceled)

In re: Nicolette  
USSN: 10/041,971  
Filed: January 9, 2002  
Page 7

25. (currently amended) The method according to claim 9, further comprising the steps in order of:

a) contacting the population of at least two cytotoxic T cells having the same MHC-haplotype restriction with a quantity of peptide released from a solid phase support, wherein said solid phase support is present in  
i) a library of molecules peptides, which peptides are attached to a plurality of solid phase supports by a releasable linker, wherein each of said solid phase supports is attached to comprising a plurality of identical copies of a single species of molecule peptide, and wherein the structure of the molecule can be determined peptide is determinable, which library of molecules peptides contains a conserved structural motif corresponding to a structural motif characteristic of peptides that associate with the MHC-haplotype to which the cytotoxic T cells are restricted; wherein said quantity of released peptide consists of an amount less than the plurality of said single species of peptide attached to said solid support; and

ii) antigen presentation means, which antigen presentation means correspond to the MHC-haplotype to which the cytotoxic T cells are restricted;

wherein the solid phase supports of the library are in separate fractions;

b) cleaving at least a portion of the releasable linker so as to release at least a portion of the molecule;  
c) evaluating whether the cytotoxic T cells recognize a molecule present in one or more of the fractions of the library of molecules;  
d) isolating one or more solid phase support(s) from the fractions; and  
e) determining the structure of a molecule on a solid phase support isolated from the fraction detecting cytotoxic T cell activation effected by the formation of a complex of a cytotoxic T cell, a single species of released peptide, and said antigen presentation means; and  
c) determining the structure of said peptide.

In re: Nicolette  
USSN: 10/041,977  
Filed: January 9, 2002

Page 8

26. (currently amended) A method for identifying a high affinity cytotoxic T cell epitope comprising:

- a) contacting a population of cytotoxic T cells having an MHC-haplotype restriction with a quantity of molecule released from a solid phase support, wherein said solid phase support is present in
  - i) a library of molecules, which molecules are attached to a plurality of solid phase supports by a releasable linker, wherein each of said solid phase supports is attached to comprising a plurality of identical copies of a single species of molecule, and wherein the structure of the molecule can be determined is determinable, which library of molecules contains a conserved structural motif corresponding to a structural motif characteristic of peptides that associate with the MHC-haplotype to which the cytotoxic T cells are restricted and, wherein every amino acid corresponding to a representative residue determined according to the method of claim 9 is utilized at the position identified for the corresponding representative residue; and wherein said quantity of released molecule consists of an amount less than the plurality of said single species of molecule attached to said solid support; and
  - ii) antigen presentation means, which antigen presentation means correspond to the MHC-haplotype to which the cytotoxic T cells are wherein the solid phase supports of the library are in separate fractions;
- b) cleaving at least a portion of the releasable linker so as to release at least a portion of the molecule;
- c) evaluating whether the cytotoxic T cells recognize a molecule present in one or more of the fractions of the library of molecules;
- d) isolating one or more solid phase support(s) from the fractions; and
- e) determining the structure of a molecule on a solid phase support isolated from the fraction detecting cytotoxic T cell activation effected by the formation of a complex of a cytotoxic T cell, a single species of released molecule, and said antigen presentation means; and
- c) determining the structure of said molecule.

27. (original) A method of identifying a protein antigen comprising:

- a) identifying the cytotoxic T cell epitope of the protein according to the method of claim 25;
- b) comparing a sequence of the T cell epitope identified in step (a)

*In re: Nicolette*  
USSN: 10/041,977  
Filed: January 9, 2002  
Page 9

with known sequences of proteins; and

- c) determining a protein having a sequence corresponding to the sequence of the T cell epitope.

28. (original) A method of identifying a protein antigen comprising:

a) identifying the cytotoxic T cell epitope of the protein according to the method of claim 26;

b) comparing a sequence of the T cell epitope identified in step (a)

with known sequences of proteins; and

- c) determining a protein having a sequence corresponding to the sequence of the T cell epitope.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**